In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Neovasc nets $35.2mm via follow-on

Executive Summary

Cardiovascular device maker Neovasc Inc. netted $35.2mm through the follow-on public offering of 6.6mm Series A units priced at $1.46. Each consists of one common share, one five-year Series A warrant to purchase a share, one two-year Series B warrant to purchase a share, and 0.40 of a two-year Series C warrant to purchase a unit comprised of one common share, one Series A warrant, and one Series B warrant. The company also sold 19.1mm Series B units at $1.46. Each Series B unit consists of either one common share or one pre-funded five-year Series D warrant to purchase a share, one Series A warrant to purchase a share, one Series B warrant to purchase a share, 0.40 of a Series C warrant to purchase a unit comprised of one common share, one Series A warrant and one Series B warrant, and 1.1765 two-year Series F warrants to purchase a share. Neovasc will use the proceeds to fund the balance of the awards granted in the litigation with CardiAQ Valve related to its Tiara technology, and to help fund the ongoing Tiara transcatheter device trial. The company concurrently completed a $32.8mm private placement.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

UsernamePublicRestriction

Register